AXXELIS Operating Group
Strategy, investment and transaction capability
- Corporate strategy
- Venture building
- Cross-border partnerships
- Investor readiness
- Licensing strategy
- Portfolio acceleration
- Operating partner ecosystem
- Transaction support
AXXELIS & AlphaMed
Since 2017, AXXELIS has brought an agile network of experienced life-science professionals together from its Swiss base, with offices in the UK and the US serving clients globally.
Within the alliance, AXXELIS contributes European life-sciences strategy and selected cross-border support for China and the US, while AlphaMed focuses on China execution and Australia/APAC market development.
AXXELIS official website ↗AXXELISStrategy
→
ExecutionOperating capability
→
AlphaMedChina commercialization
→
Value CreationLong-term growth
Global Alliance Footprint
AlphaMed Solutions
China market and commercialization capability
- China regulatory strategy
- Medical affairs
- Clinical strategy
- Commercial launch
- KOL development
- Pricing and positioning
- Distribution strategy
- Market access and commercial operations
Investor Support
China market validation, commercial due diligence, cross-border opportunity assessment and market-attractiveness analysis.
Biotech Companies
China entry strategy, licensing support, launch preparation, medical affairs, KOL engagement and commercial execution.
Industry Partners
Distribution partnerships, commercial alliances, product launches, cross-border expansion and business development.